Why Boston Scientific Corporation (BSX) stock moved
Boston Scientific Corporation (BSX) shares tumbled 5.8% to $42.43 as of October 29, 2026, a significant decline from the prior close of $45.06. BestStocks flagged the session as a major change for BSX. Below, we break down what changed for BSX, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
BSX fell 5.8% to $42.43
BSX tumbled 5.8% in its latest session, moving from $45.06 to $42.43.
What it means for Boston Scientific Corporation investors
For Boston Scientific Corporation investors, the recent signals add up to a bearish shift. On the constructive side: Positive price momentum. Weighing against that: Sharp 5.8% decline — elevated risk; High volume 3.6x on decline — distribution signal. Wall Street's consensus price target sits at $58.15, implying +37.0% upside from $42.43. Over the past 90 days analysts logged 0 upgrades and 2 downgrades. BestStocks rates the overall signal quality medium (68/100). With earnings roughly 97 days out, the next report is the most likely near-term test of the move.
BSX price reaction
BSX last traded at $42.43, down $2.63 (-5.84%) from the previous close of $45.06. The session traded on 3.6× average volume (extreme), so the move carried above-average conviction. Over the past month the stock has ranged between $41.58 and $46.01, and it currently sits about 19% of the way up that band.
Bullish and bearish analyst opinions on Boston Scientific Corporation (BSX)
The consensus analyst price target on Boston Scientific Corporation (BSX) is $58.15, 37.0% above the recent $42.43. Over the past 90 days analysts logged 0 upgrades, 8 maintains, and 2 downgrades. Here is how the bullish and bearish cases on BSX line up.
The bullish case
- Wall Street's consensus price target of $58.15 implies +37.0% upside from $42.43.
- The Street's most bullish target is $71.00 (+67.3%).
- Positive price momentum.
The bearish case
- 2 analyst downgrades in the past 90 days, most recently Citigroup to Neutral (2026-09-17).
- Sharp 5.8% decline — elevated risk.
- High volume 3.6x on decline — distribution signal.
- Boston Scientific slashed earnings guidance following a cyberattack and other operational challenges, as reported by Barron's and The Wall Street Journal.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 28, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for BSX
In-depth BSX event analyses
Frequently asked questions about BSX
Why did Boston Scientific Corporation (BSX) stock move?
BSX tumbled 5.8% to $42.43. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did BSX stock fall?
BSX lost 5.84% ($2.63) versus the prior close of $45.06, last trading at $42.43 on 3.6× average volume.
When is Boston Scientific Corporation's next earnings date?
BSX's next earnings report is estimated for 2027-02-03 — about 97 days away.
What is the analyst price target for BSX?
The consensus analyst price target for BSX is $58.15, about 37.0% above the current $42.43. Over the past 90 days, analysts recorded 0 upgrades, 8 maintains, and 2 downgrades.
How BestStocks tracks BSX
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared BSX-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for BSX, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 29, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.